BSX - Boston Scientific Corporation
| Previous close | 51.40 |
| Open | 51.33 |
| Bid | 50.57 x 800 |
| Ask | 50.58 x 1200 |
| Day's range | 50.42 - 51.52 |
| 52-week range | 34.98 - 54.17 |
| Volume | |
| Avg. volume | 9,375,525 |
| Market cap | 72.6B |
| Beta (5Y monthly) | 0.80 |
| PE ratio (TTM) | 85.59 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Here's Why You Should Retain AMN Healthcare (AMN) Stock for Now
Investors remain optimistic about AMN Healthcare's (AMN) broad array of services.
- Simply Wall St.
Boston Scientific (NYSE:BSX) shareholders have earned a 8.6% CAGR over the last five years
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But the truth is...
- Zacks
Here's Why You Should Retain PacBio (PACB) Stock for Now
PacBio's (PACB) product development activities raise optimism about the stock.
- Zacks
Veeva Systems (VEEV) Beats on Q1 Earnings, Ups FY24 Outlook
Veeva Systems' (VEEV) fiscal Q1 results reflect impressive performances by both segments.
- Zacks
Here's Why You Should Retain DaVita (DVA) Stock for Now
Investors remain optimistic about DaVita (DVA) due to the strength of its DaVita Kidney Care.
- Simply Wall St.
Investors Could Be Concerned With Boston Scientific's (NYSE:BSX) Returns On Capital
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...
- Zacks
Veeva Systems (VEEV) Extends Tie-Up With Lotus Clinical
Veeva Systems (VEEV) expands its partnership with Lotus Clinical to accelerate clinical trials.
- Zacks
Boston Scientific (BSX) Rises 26.4%: Will the Rally Continue?
Boston Scientific (BSX) gains from strong improvement in organic sales, indicating a solid rebound in the legacy business.
- Zacks
Is Augmedix (AUGX) Outperforming Other Medical Stocks This Year?
Here is how Augmedix, Inc. (AUGX) and Boston Scientific (BSX) have performed compared to their sector so far this year.
- Zacks
Catalent (CTLT) Expands Its Facility Capabilities in Shiga
Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Supply Services network.
- Simply Wall St.
Can Boston Scientific Corporation (NYSE:BSX) Performance Keep Up Given Its Mixed Bag Of Fundamentals?
Boston Scientific's (NYSE:BSX) stock is up by 9.1% over the past three months. However, the company's financials look a...
- Zacks
Why Is Boston Scientific (BSX) Down 0.9% Since Last Earnings Report?
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Veeva Systems (VEEV) Offerings Adopted by Minaris Regenerative
Veeva Systems' (VEEV) Vault Quality Suite applications are expected to aid the CDMO to modernize its operations and streamline its quality processes globally.
- Zacks
Medtronic (MDT) Q4 Earnings Beat Estimates, Margins Down
Strong growth in the Cardiovascular, Medical Surgical, and Neuroscience portfolios, and in Diabetes markets drove Medtronic (MDT) Q4 revenues.
- Zacks
Masimo's (MASI) Platform Expansion to Boost Patient Monitoring
Masimo's (MASI) latest expansion to its HEOS platform will likely revolutionize health and wellness tracking by allowing connected care as consumers become tetherless and smartphone-less.
- Zacks
Boston Scientific (BSX) Gains From Acquisitions, New Launches
Boston Scientific (BSX) remains excited about 2023 performance and expects to continue to outpace its peers within the EMEA market.
- Zacks
Accuray (ARAY) Hits 52-Week High: What's Aiding the Stock?
Investors are optimistic about Accuray's (ARAY) solid product portfolio.
- Zacks
Veeva Systems' (VEEV) New Tie-Up to Improve Clinical Trials
Veeva Systems' (VEEV) latest collaboration is expected to advance the patient experience in clinical trials.
- Simply Wall St.
Boston Scientific Corporation's (NYSE:BSX) Intrinsic Value Is Potentially 20% Below Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, Boston Scientific fair value estimate is US$41.38 Current...
- Zacks
Avantor's (AVTR) New Tie-Up to Improve Lab Inventory Management
Avantor's (AVTR) latest partnership is expected to significantly optimize labs' inventory management and the overall workflow.
- Zacks
3 Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
- Zacks
3 Reasons to Hold Inspire Medical (INSP) Stock in Your Portfolio
Investors continue to be optimistic about Inspire Medical (INSP) on the back of its product innovations.
- Zacks
BD's (BDX) Latest Product Launch to Boost Research Outcome
BD's (BDX) latest cell sorting technology is expected to speed up the process of cell sorting and allow researchers to answer complex biological questions.
- Zacks
HCA Healthcare (HCA) Gains 29% in a Year: More Upside Left?
HCA Healthcare (HCA) is well-poised for growth on the back of higher revenues, a diversified treatment network and sound operating cash flows.
- Zacks
Are Medical Stocks Lagging Boston Scientific (BSX) This Year?
Here is how Boston Scientific (BSX) and Aravive (ARAV) have performed compared to their sector so far this year.
